VCs Raise Cash For New Deals; Five Biotechs Find Funding

Venture capitalists raised $12bn for new US-based funds in the first quarter of 2016, including a handful of VC firms that invest in biotechnology, which is good news for early-stage drug developers that hope to close new funding rounds, like their peers at Entasis Therapeutics did recently.